Navigation Links
Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka

LOS ANGELES, May 15, 2013 /PRNewswire/ -- On May 8, 2013, Dr. Rongxiang Xu , the founder of "human body regenerative restoration science" and a renowned life and medical scientist who is believed to be the only person who has patented the technology for direct regeneration of damaged organs has filed a lawsuit against Dr. Shinya Yamanaka , one of the winners of the 2012 Nobel Prize in Physiology or Medicine in the Superior Court of California, County of San Francisco. The lawsuit filed alleges, among other things, deception by Dr. Shinya Yamanaka .


According to Dr. Xu's attorney, a previous lawsuit was filed by Dr. Xu against the Nobel Assembly on December 3, 2012, urging the Assembly to clarify certain statements made in conjunction with awarding the 2012 Nobel Prize in Physiology or Medicine. Unfortunately, no response clarifying the truth about the science has been received as the case is still pending. Therefore, Dr. Xu has filed another lawsuit directly against Dr. Yamanaka, for alleged deceptive practices employed by Dr. Yamanaka.

Dr. Xu's attorney stated that Dr. Yamanaka's published statements labeling his artificially transgenic cell study as "induction of somatic cells into stem cells", which was the patented technology of Dr. Xu, has caused substantial damages to his reputation and company. Dr. Xu claims that Dr. Yamanaka has deceived a number of well-intentioned professionals into exploration and research on the life science forefront. However, Dr. Xu believes that Dr. Yamanaka has steered these professionals down the wrong path. For example, Dr. Xu believes that even the US government was misled into Dr. Yamanaka's hype when the 2008 state of the union address mentioned favoring a way to reprogram adult skin cells to act like embryonic stem cells, as claimed by Dr. Yamanaka. Dr. Xu believes hundreds of millions in taxpayers' money has been wasted in funding such false science.

The Nobel Assembly granted Dr. Yamanaka the Prize in Physiology or Medicine in 2012, acclaiming his artificially transgenic cells created human regenerative potential. Considering the foreseeable consequences threatening human lives, Dr. Xu is working to stop such deception through the legal process.

Dr. Yamanaka labeled his artificial cell produced by oncogene transferring as "somatic cell induction into pluripotent stem cells", i.e. he claimed his artificially transgenic cell study in the name of the plaintiff's patented technology and called it iPSC in short, which was quickly endorsed and followed by a group of prestigious scientists expecting to solve the ethic issue of embryonic stem cell study.

This term used by Dr. Yamanaka is the core of Dr. Xu's patents, including US Patent 6991813 and Dr. Xu alleges that Dr. Yamanaka's study actually has nothing to do with stem cell. Dr. Yamanaka admitted in his article published in Cell Stem Cell magazine in 2012 that he didn't obtain natural pluripotent stem cells by somatic cell induction. According to Dr. Xu, it is critical to ask why such a ridiculous scientific scam has been prevailing worldwide for the past few years.

Human somatic cell induction into pluripotent stem cell is the core content of the Dr. Xu's patented scientific route of "regeneration of damaged organs" and has been accomplished in clinical application. However, this technology that allows "regeneration of damaged organs" has been hindered from benefiting the general public due to the scientific scam by Dr. Yamanaka, depriving the chances of tens of thousands of patients for getting access to innovative science and technology for cures.

The scientific route of "developing drugs to regenerate damaged organs" has been labeled one of the nation's main topics of focus, and was also discussed by president Obama in his 2013 State of the Union Address, where he stated "Now, if we want to make the best products, we also have to invest in the best ideas. Every dollar we invested to map the human genome returned $140 to our economy. Every dollar. Today, our scientists are mapping the human brain to unlock the answers to Alzheimer's. We're developing drugs to regenerate damaged organs, devising new materials to make batteries 10 times more powerful. Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race. We need to make those investments."

Dr. Xu is thankful for the Obama administration's acknowledgement of this vital area of organ regeneration, and feels that this direction is a blessing for Americans and people worldwide.

Please contact Jane Westgate 336.608.4439 or Cheryl Riley 703.683.1798. The Plaintiff is represented by the Ardent Law Group in California.

SOURCE Mebo International; Ardent Law Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Mold Plagues New Florida Home Owners, Environmental Impact Assessment Company AGC Environmental Offers Them Insights on Obtaining Expert Mold Remediation and Inspection
2. Defying Industry Trends, BBK Worldwide Expands Ownership From Within
3. Riveting NY Times Bestselling Biotech Thriller, WIRED, Now Only $5.95 for Kindle Owners
4. Mold Remediation Products Offered In Response To Senators Pledge To Help Homeowners With Mold, Details Where to Get the Sprays
5. Rust Gets Toyota Recalling Its Tacoma; Hub on Wheels Advises Car Owners to Deal With Any Other Car Rust Problem with Rusterizer
6. Tropical Storm Debby Pounds Florida With Heavy Rain. Green Bean Buddy Gives Reason Why Home Owners Should Prepare For Mold Outbreaks
7. Bed Bugs Bite on Businesses, Green Bean Buddy Advises Owners to Fight Back With a Non-Toxic Bed Bug Bully Product
8. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
9. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
10. Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
11. The Research Foundation for The State University of New York Enters Site License Agreement with 2Market Information Inc., Publisher of Technology Transfer Tactics
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):